vTv Therapeutics Inc.VTVTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 50% recommend buying.

Consensus Rating

Buy

14 analysts·Moderate coverage

50%

Rating Distribution

Strong Buy

00%

Buy

750%

Hold

750%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 39% higher.

Bear Case

$47.00

+27%

Consensus

$51.33

+39%

Bull Case

$58.00

+57%

Price Range14 analysts

Low

Consensus

High

$47.00

$58.00

Current Target

Current Price

$37.00

Upside to Target

$14.33

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-4.31(4 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-46.79%

EPS—

FY2028

Rev+3686.15%

EPS—

FY2029

Rev+273.28%

EPS—

Earnings Surprises

Beat rate:50%(6/12 quarters)

Avg surprise:-300.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 27, 2026BTIG

vTv Therapeutics price target raised to $49 from $40 at BTIG

Target:$49.00

+44.7%from $33.86

Jan 22, 2026Roth Capital

vTv Therapeutics initiated with a Buy at Roth Capital

Target:$58.00

+72.9%from $33.54

Dec 19, 2025H.C. Wainwright

vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright

Target:$47.00

+29.5%from $36.30

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance